Pulmonary hypertension and right ventricular dysfunction in left heart disease (group 2 pulmonary hypertension)

Progress in Cardiovascular Diseases

Volumn 55, Issue 2, 2012, Pages 104-118

  Wilson, Sean R ^a   Ghio, Stefano ^b   Scelsi, Laura ^b   Horn, Evelyn M ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Heart failure with preserved ejection fraction; Pulmonary hypertension; Right ventricular dysfunction; Systolic dysfunction; Valvular disease

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE; DIURETIC AGENT; PLACEBO; SILDENAFIL;

AORTA STENOSIS; ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE SEVERITY; DISEASE SURVEILLANCE; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; HEART EJECTION FRACTION; HEART HEMODYNAMICS; HEART RIGHT VENTRICLE FAILURE; HEART TRANSPLANTATION; HUMAN; LEFT VENTRICULAR ASSIST DEVICE; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; MITRAL VALVE DISEASE; MITRAL VALVE REPLACEMENT; NONHUMAN; PATHOPHYSIOLOGY; PROGNOSIS; PULMONARY HYPERTENSION; RISK ASSESSMENT; RISK FACTOR; TREATMENT CONTRAINDICATION; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT PLANNING;

DIAGNOSTIC IMAGING; HUMANS; HYPERTENSION, PULMONARY; PROGNOSIS; PULMONARY WEDGE PRESSURE; SEVERITY OF ILLNESS INDEX; STROKE VOLUME; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR DYSFUNCTION, RIGHT;

EID: 84866630341     PISSN: 00330620     EISSN: 18731740     Source Type: Journal    
DOI: 10.1016/j.pcad.2012.07.007     Document Type: Article

References (153)

1. Rosenkranz S., Bonderman D., Buerke M., et al. Pulmonary hypertension due to left heart disease: updated Recommendations of the Cologne Consensus Conference 2011. Int J Cardiol 2011, 154(Suppl. 1):S34-S44.
2. Topol E.J., Traill T.A., Fortuin N.J. Hypertensive hypertrophic cardiomyopathy of the elderly. N Engl J Med 1985, 312:277-283.
3. Fonarow G.C., Stough W.G., Abraham W.T., et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. J Am Coll Cardiol 2007, 50:768-777.
4. Owan T.E., Hodge D.O., Herges R.M., et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006, 355:251-259.
5. Tribouilloy C., Rusinaru D., Mahjoub H., et al. Prognosis of heart failure with preserved ejection fraction: a 5 year prospective population-based study. Eur Heart J 2008, 29:339-347.
6. Yancy C.W., Lopatin M., Stevenson L.W., et al. Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. J Am Coll Cardiol 2006, 47:76-84.
7. Bhatia R.S., Tu J.V., Lee D.S., et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 2006, 355:260-269.
8. Yu C.M., Lin H., Yang H., et al. Progression of systolic abnormalities in patients with "isolated" diastolic heart failure and diastolic dysfunction. Circulation 2002, 105:1195-1201.
9. Borlaug B.A., Lam C.S., Roger V.L., et al. Contractility and ventricular systolic stiffening in hypertensive heart disease insights into the pathogenesis of heart failure with preserved ejection fraction. J Am Coll Cardiol 2009, 54:410-418.
10. Borlaug B.A., Nishimura R.A., Sorajja P., et al. Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction. Circ Heart Fail 2010, 3:588-595.
11. Borlaug B.A., Olson T.P., Lam C.S., et al. Global cardiovascular reserve dysfunction in heart failure with preserved ejection fraction. J Am Coll Cardiol 2010, 56:845-854.
12. Kjaergaard J., Akkan D., Iversen K.K., et al. Prognostic importance of pulmonary hypertension in patients with heart failure. Am J Cardiol 2007, 99:1146-1150.
13. Lam C.S., Roger V.L., Rodeheffer R.J., et al. Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. J Am Coll Cardiol 2009, 53:1119-1126.
14. Phan T.T., Abozguia K., Nallur Shivu G., et al. Heart failure with preserved ejection fraction is characterized by dynamic impairment of active relaxation and contraction of the left ventricle on exercise and associated with myocardial energy deficiency. J Am Coll Cardiol 2009, 54:402-409.
15. 2+ signaling and cytoskeletal reorganization. Circ Res 2010, 106:1103-1116.
16. Huang W., Kingsbury M.P., Turner M.A., et al. Capillary filtration is reduced in lungs adapted to chronic heart failure: morphological and haemodynamic correlates. Cardiovasc Res 2001, 49:207-217.
17. Tsukimoto K., Mathieu-Costello O., Prediletto R., et al. Ultrastructural appearances of pulmonary capillaries at high transmural pressures. J Appl Physiol 1991, 71:573-582.
18. Kurdak S.S., Namba Y., Fu Z., et al. Effect of increased duration of high perfusion pressure on stress failure of pulmonary capillaries. Microvasc Res 1995, 50:235-248.
19. West J.B., Mathieu-Costello O. Vulnerability of pulmonary capillaries in heart disease. Circulation 1995, 92:622-631.
20. Jasmin J.F., Calderone A., Leung T.K., et al. Lung structural remodeling and pulmonary hypertension after myocardial infarction: complete reversal with irbesartan. Cardiovasc Res 2003, 58:621-631.
21. Negrini D., Passi A., de Luca G., et al. Pulmonary interstitial pressure and proteoglycans during development of pulmonary edema. Am J Physiol 1996, 270:H2000-H2007.
22. Palestini P., Calvi C., Conforti E., et al. Composition, biophysical properties, and morphometry of plasma membranes in pulmonary interstitial edema. Am J Physiol Lung Cell Mol Physiol 2002, 282:L1382-L1390.
23. Townsley M.I., Fu Z., Mathieu-Costello O., et al. Pulmonary microvascular permeability. Responses to high vascular pressure after induction of pacing-induced heart failure in dogs. Circ Res 1995, 77:317-325.
24. West J.B. Invited review: pulmonary capillary stress failure. J Appl Physiol 2000, 89:2483-2489. [discussion 97].
25. Hunter J.J., Chien K.R. Signaling pathways for cardiac hypertrophy and failure. N Engl J Med 1999, 341:1276-1283.
26. Berg J.T., Breen E.C., Fu Z., et al. Alveolar hypoxia increases gene expression of extracellular matrix proteins and platelet-derived growth factor-B in lung parenchyma. Am J Respir Crit Care Med 1998, 158:1920-1928.
27. Conforti E., Fenoglio C., Bernocchi G., et al. Morpho-functional analysis of lung tissue in mild interstitial edema. Am J Physiol Lung Cell Mol Physiol 2002, 282:L766-L774.
28. Guazzi M. Alveolar gas diffusion abnormalities in heart failure. J Card Fail 2008, 14:695-702.
29. Delgado J.F., Conde E., Sanchez V., et al. Pulmonary vascular remodeling in pulmonary hypertension due to chronic heart failure. Eur J Heart Fail 2005, 7:1011-1016.
30. Jones P.L., Cowan K.N., Rabinovitch M. Tenascin-C, proliferation and subendothelial fibronectin in progressive pulmonary vascular disease. Am J Pathol 1997, 150:1349-1360.
31. Jones P.L., Crack J., Rabinovitch M. Regulation of tenascin-C, a vascular smooth muscle cell survival factor that interacts with the alpha v beta 3 integrin to promote epidermal growth factor receptor phosphorylation and growth. J Cell Biol 1997, 139:279-293.
32. Mandegar M., Fung Y.C., Huang W., et al. Cellular and molecular mechanisms of pulmonary vascular remodeling: role in the development of pulmonary hypertension. Microvasc Res 2004, 68:75-103.
33. Ray L., Mathieu M., Jespers P., et al. Early increase in pulmonary vascular reactivity with overexpression of endothelin-1 and vascular endothelial growth factor in canine experimental heart failure. Exp Physiol 2008, 93:434-442.
34. Heath D., Edwards J.E. Histological changes in the lung in diseases associated with pulmonary venous hypertension. Br J Dis Chest 1959, 53:8-18.
35. Moraes D.L., Colucci W.S., Givertz M.M. Secondary pulmonary hypertension in chronic heart failure: the role of the endothelium in pathophysiology and management. Circulation 2000, 102:1718-1723.
36. Cooper C.J., Jevnikar F.W., Walsh T., et al. The influence of basal nitric oxide activity on pulmonary vascular resistance in patients with congestive heart failure. Am J Cardiol 1998, 82:609-614.
37. Ooi H., Colucci W.S., Givertz M.M. Endothelin mediates increased pulmonary vascular tone in patients with heart failure: demonstration by direct intrapulmonary infusion of sitaxsentan. Circulation 2002, 106:1618-1621.
38. Blitzer M.L., Loh E., Roddy M.A., et al. Endothelium-derived nitric oxide regulates systemic and pulmonary vascular resistance during acute hypoxia in humans. J Am Coll Cardiol 1996, 28:591-596.
39. Daraseliia G.A., Bochoridze L.D. Carotenoid pigments of Mycobacterium brevicale. Mikrobiol Zh 1979, 41:685-687.
40. Fukuroda T., Kobayashi M., Ozaki S., et al. Endothelin receptor subtypes in human versus rabbit pulmonary arteries. J Appl Physiol 1994, 76:1976-1982.
41. Shahbaz A.U., Sun Y., Bhattacharya S.K., et al. Fibrosis in hypertensive heart disease: molecular pathways and cardioprotective strategies. J Hypertens 2010, 28(Suppl. 1):S25-S32.
42. Tsutamoto T., Wada A., Maeda Y., et al. Relation between endothelin-1 spillover in the lungs and pulmonary vascular resistance in patients with chronic heart failure. J Am Coll Cardiol 1994, 23:1427-1433.
43. Kobayashi T., Miyauchi T., Sakai S., et al. Expression of endothelin-1, ETA and ETB receptors, and ECE and distribution of endothelin-1 in failing rat heart. Am J Physiol 1999, 276:H1197-H1206.
44. Cody R.J., Haas G.J., Binkley P.F., et al. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation 1992, 85:504-509.
45. Rodeheffer R.J., Lerman A., Heublein D.M., et al. Increased plasma concentrations of endothelin in congestive heart failure in humans. Mayo Clin Proc 1992, 67:719-724.
46. Guarda E., Katwa L.C., Myers P.R., et al. Effects of endothelins on collagen turnover in cardiac fibroblasts. Cardiovasc Res 1993, 27:2130-2134.
47. Du L., Sullivan C.C., Chu D., et al. Signaling molecules in nonfamilial pulmonary hypertension. N Engl J Med 2003, 348:500-509.
48. Hoffmann J., Yin J., Kukucka M., et al. Mast cells promote lung vascular remodelling in pulmonary hypertension. Eur Respir J 2011, 37:1400-1410.
49. Montani D., Lang I.M. Mast cells: bridging the gap between pre- and post-capillary pulmonary hypertension?. Eur Respir J 2011, 37:1303-1305.
50. Kuznetsova T., Herbots L., Lopez B., et al. Prevalence of left ventricular diastolic dysfunction in a general population. Circ Heart Fail 2009, 2:105-112.
51. Bursi F., McNallan S.M., Redfield M.M., et al. Pulmonary pressures and death in heart failure: a community study. J Am Coll Cardiol 2012, 59:222-231.
52. Tsuchihashi-Makaya M., Hamaguchi S., Kinugawa S., et al. Characteristics and outcomes of hospitalized patients with heart failure and reduced vs preserved ejection fraction. Report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). Circ J 2009, 73:1893-1900.
53. Fan Z.R. A combination method of elevation, retrusion of the palate and reduction of the transverse diameter of the pharyngeal cavity in the repair of cleft palate. Report of 51 cases. Zhonghua Zheng Xin 1989, 5:255-256.
54. Damy T., Goode K.M., Kallvikbacka-Bennett A., et al. Determinants and prognostic value of pulmonary arterial pressure in patients with chronic heart failure. Eur Heart J 2010, 31:2280-2290.
55. Butler J., Chomsky D.B., Wilson J.R. Pulmonary hypertension and exercise intolerance in patients with heart failure. J Am Coll Cardiol 1999, 34:1802-1806.
56. Magana-Serrano J.A., Almahmeed W., Gomez E., et al. Prevalence of heart failure with preserved ejection fraction in Latin American, Middle Eastern, and North African Regions in the I PREFER study (Identification of Patients With Heart Failure and PREserved Systolic Function: an epidemiological regional study). Am J Cardiol 2011, 108:1289-1296.
57. Thenappan T., Shah S.J., Gomberg-Maitland M., et al. Clinical characteristics of pulmonary hypertension in patients with heart failure and preserved ejection fraction. Circ Heart Fail 2011, 4:257-265.
58. European Study Group on Diastolic Heart Failure How to diagnose diastolic heart failure. Eur Heart J 1998, 19:990-1003.
59. Paulus W.J., Tschope C., Sanderson J.E., et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 2007, 28:2539-2550.
60. Vasan R.S., Levy D. Defining diastolic heart failure: a call for standardized diagnostic criteria. Circulation 2000, 101:2118-2121.
61. Yturralde R.F., Gaasch W.H. Diagnostic criteria for diastolic heart failure. Prog Cardiovasc Dis 2005, 47:314-319.
62. Nagueh S.F., Appleton C.P., Gillebert T.C., et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr 2009, 22:107-133.
63. Champion H.C., Michelakis E.D., Hassoun P.M. Comprehensive invasive and noninvasive approach to the right ventricle-pulmonary circulation unit: state of the art and clinical and research implications. Circulation 2009, 120:992-1007.
64. Nagaya N., Nishikimi T., Okano Y., et al. Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension. J Am Coll Cardiol 1998, 31:202-208.
65. Carlsen C.M., Bay M., Kirk V., et al. Prevalence and prognosis of heart failure with preserved ejection fraction and elevated N-terminal pro brain natriuretic peptide: a 10-year analysis from the Copenhagen Hospital Heart Failure Study. Eur J Heart Fail 2012, 14:240-247.
66. Sallin E.A. Fiber orientation and ejection fraction in the human left ventricle. Biophys J 1969, 9:954-964.
67. Haddad F., Hunt S.A., Rosenthal D.N., et al. Right ventricular function in cardiovascular disease, part I: anatomy, physiology, aging, and functional assessment of the right ventricle. Circulation 2008, 117:1436-1448.
68. James T.N. Anatomy of the crista supraventricularis: its importance for understanding right ventricular function, right ventricular infarction and related conditions. J Am Coll Cardiol 1985, 6:1083-1095.
69. Anderson R.H., Sanchez-Quintana D., Niederer P., et al. Structural-functional correlates of the 3-dimensional arrangement of the myocytes making up the ventricular walls. J Thorac Cardiovasc Surg 2008, 136:10-18.
70. Castella M., Buckberg G.D., Saleh S., et al. Structure function interface with sequential shortening of basal and apical components of the myocardial band. Eur J Cardiothorac Surg 2005, 27:980-987.
71. de Vroomen M., Cardozo R.H., Steendijk P., et al. Improved contractile performance of right ventricle in response to increased RV afterload in newborn lamb. Am J Physiol Heart Circ Physiol 2000, 278:H100-H105.
72. Hon J.K., Steendijk P., Khan H., et al. Acute effects of pulmonary artery banding in sheep on right ventricle pressure-volume relations: relevance to the arterial switch operation. Acta Physiol Scand 2001, 172:97-106.
73. Saleh S., Liakopoulos O.J., Buckberg G.D. The septal motor of biventricular function. Eur J Cardiothorac Surg 2006, 29(Suppl. 1):S126-S138.
74. Damiano R.J., La Follette P., Cox J.L., et al. Significant left ventricular contribution to right ventricular systolic function. Am J Physiol 1991, 261:H1514-H1524.
75. Janicki J.S., Weber K.T. The pericardium and ventricular interaction, distensibility, and function. Am J Physiol 1980, 238:H494-H503.
76. Maruyama Y., Ashikawa K., Isoyama S., et al. Mechanical interactions between four heart chambers with and without the pericardium in canine hearts. Circ Res 1982, 50:86-100.
77. Santamore W.P., Lynch P.R., Meier G., et al. Myocardial interaction between the ventricles. J Appl Physiol 1976, 41:362-368.
78. Feneley M.P., Gavaghan T.P., Baron D.W., et al. Contribution of left ventricular contraction to the generation of right ventricular systolic pressure in the human heart. Circulation 1985, 71:473-480.
79. Peters J., Kindred M.K., Robotham J.L. Transient analysis of cardiopulmonary interactions. I. Diastolic events. J Appl Physiol 1988, 64:1506-1517.
80. Peters J., Kindred M.K., Robotham J.L. Transient analysis of cardiopulmonary interactions. II. Systolic events. J Appl Physiol 1988, 64:1518-1526.
81. Weyman A.E., Wann S., Feigenbaum H., et al. Mechanism of abnormal septal motion in patients with right ventricular volume overload: a cross-sectional echocardiographic study. Circulation 1976, 54:179-186.
82. Dell'Italia L.J., Starling M.R., Blumhardt R., et al. Comparative effects of volume loading, dobutamine, and nitroprusside in patients with predominant right ventricular infarction. Circulation 1985, 72:1327-1335.
83. Goldstein J.A., Harada A., Yagi Y., et al. Hemodynamic importance of systolic ventricular interaction, augmented right atrial contractility and atrioventricular synchrony in acute right ventricular dysfunction. J Am Coll Cardiol 1990, 16:181-189.
84. Gan C.T., Holverda S., Marcus J.T., et al. Right ventricular diastolic dysfunction and the acute effects of sildenafil in pulmonary hypertension patients. Chest 2007, 132:11-17.
85. Chen E.P., Craig D.M., Bittner H.B., et al. Pharmacological strategies for improving diastolic dysfunction in the setting of chronic pulmonary hypertension. Circulation 1998, 97:1606-1612.
86. Spinarova L., Meluzin J., Toman J., et al. Right ventricular dysfunction in chronic heart failure patients. Eur J Heart Fail 2005, 7:485-489.
87. Juilliere Y., Barbier G., Feldmann L., et al. Additional predictive value of both left and right ventricular ejection fractions on long-term survival in idiopathic dilated cardiomyopathy. Eur Heart J 1997, 18:276-280.
88. Voelkel N.F., Quaife R.A., Leinwand L.A., et al. Right ventricular function and failure: report of a National Heart, Lung, and Blood Institute working group on cellular and molecular mechanisms of right heart failure. Circulation 2006, 114:1883-1891.
89. Ghio S., Gavazzi A., Campana C., et al. Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. J Am Coll Cardiol 2001, 37:183-188.
90. Berkowitz R., Alhaj E., Manchikalapudi R.B., et al. Determinants of right ventricular failure in patients admitted with acute left heart failure. Congest Heart Fail 2010, 16:243-248.
91. Moustapha A., Lim M., Saikia S., et al. Interrogation of the tricuspid annulus by Doppler tissue imaging in patients with chronic pulmonary hypertension: implications for the assessment of right-ventricular systolic and diastolic function. Cardiology 2001, 95:101-104.
92. Meluzin J., Spinarova L., Bakala J., et al. Pulsed Doppler tissue imaging of the velocity of tricuspid annular systolic motion; a new, rapid, and non-invasive method of evaluating right ventricular systolic function. Eur Heart J 2001, 22:340-348.
93. Kitabatake A., Inoue M., Asao M., et al. Noninvasive evaluation of pulmonary hypertension by a pulsed Doppler technique. Circulation 1983, 68:302-309.
94. Puwanant S., Priester T.C., Mookadam F., et al. Right ventricular function in patients with preserved and reduced ejection fraction heart failure. Eur J Echocardiogr 2009, 10:733-737.
95. Ghio S., Recusani F., Klersy C., et al. Prognostic usefulness of the tricuspid annular plane systolic excursion in patients with congestive heart failure secondary to idiopathic or ischemic dilated cardiomyopathy. Am J Cardiol 2000, 85:837-842.
96. Agarwal R., Shah S.J., Foreman A.J., et al. Risk assessment in pulmonary hypertension associated with heart failure and preserved ejection fraction. J Heart Lung Transplant 2012, 31:467-477.
97. Massie B.M., Carson P.E., McMurray J.J., et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008, 359:2456-2467.
98. Hernandez A.F., Hammill B.G., O'Connor C.M., et al. Clinical effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) Registry. J Am Coll Cardiol 2009, 53:184-192.
99. Yusuf S., Pfeffer M.A., Swedberg K., et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003, 362:777-781.
100. Paulus W.J., van Ballegoij J.J. Treatment of heart failure with normal ejection fraction: an inconvenient truth!. J Am Coll Cardiol 2010, 55:526-537.
101. The SOLVD Investigators Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991, 325:293-302.
102. Paulus W.J., Vantrimpont P.J., Shah A.M. Acute effects of nitric oxide on left ventricular relaxation and diastolic distensibility in humans. Assessment by bicoronary sodium nitroprusside infusion. Circulation 1994, 89:2070-2078.
103. Tsai E.J., Kass D.A. Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics. Pharmacol Ther 2009, 122:216-238.
104. Takimoto E., Champion H.C., Li M., et al. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med 2005, 11:214-222.
105. Borlaug B.A., Melenovsky V., Marhin T., et al. Sildenafil inhibits beta-adrenergic-stimulated cardiac contractility in humans. Circulation 2005, 112:2642-2649.
106. Vlachopoulos C., Hirata K., O'Rourke M.F. Effect of sildenafil on arterial stiffness and wave reflection. Vasc Med 2003, 8:243-248.
107. Katz S.D., Balidemaj K., Homma S., et al. Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure. J Am Coll Cardiol 2000, 36:845-851.
108. Lewis G.D., Shah R., Shahzad K., et al. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation 2007, 116:1555-1562.
109. Guazzi M., Tumminello G., Di Marco F., et al. The effects of phosphodiesterase-5 inhibition with sildenafil on pulmonary hemodynamics and diffusion capacity, exercise ventilatory efficiency, and oxygen uptake kinetics in chronic heart failure. J Am Coll Cardiol 2004, 44:2339-2348.
110. Silberman G.A., Fan T.H., Liu H., et al. Uncoupled cardiac nitric oxide synthase mediates diastolic dysfunction. Circulation 2010, 121:519-528.
111. Moens A.L., Takimoto E., Tocchetti C.G., et al. Reversal of cardiac hypertrophy and fibrosis from pressure overload by tetrahydrobiopterin: efficacy of recoupling nitric oxide synthase as a therapeutic strategy. Circulation 2008, 117:2626-2636.
112. Fukuta H., Sane D.C., Brucks S., et al. Statin therapy may be associated with lower mortality in patients with diastolic heart failure: a preliminary report. Circulation 2005, 112:357-363.
113. Xu E.Z., Kantores C., Ivanovska J., et al. Rescue treatment with a Rho-kinase inhibitor normalizes right ventricular function and reverses remodeling in juvenile rats with chronic pulmonary hypertension. Am J Physiol Heart Circ Physiol 2010, 299:H1854-H1864.
114. Galie N., Hoeper M.M., Humbert M., et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009, 30:2493-2537.
115. Drazner M.H., Hamilton M.A., Fonarow G., et al. Relationship between right and left-sided filling pressures in 1000 patients with advanced heart failure. J Heart Lung Transplant 1999, 18:1126-1132.
116. Cappola T.P., Felker G.M., Kao W.H., et al. Pulmonary hypertension and risk of death in cardiomyopathy: patients with myocarditis are at higher risk. Circulation 2002, 105:1663-1668.
117. Enriquez-Sarano M., Rossi A., Seward J.B., et al. Determinants of pulmonary hypertension in left ventricular dysfunction. J Am Coll Cardiol 1997, 29:153-159.
118. Capomolla S., Febo O., Guazzotti G., et al. Invasive and non-invasive determinants of pulmonary hypertension in patients with chronic heart failure. J Heart Lung Transplant 2000, 19:426-438.
119. Guazzi M., Arena R. Pulmonary hypertension with left-sided heart disease. Nat Rev Cardiol 2010, 7:648-659.
120. Haddad F., Kudelko K., Mercier O., et al. Pulmonary hypertension associated with left heart disease: characteristics, emerging concepts, and treatment strategies. Prog Cardiovasc Dis 2011, 54:154-167.
121. Mikhail G., Chester A.H., Gibbs J.S., et al. Role of vasoactive mediators in primary and secondary pulmonary hypertension. Am J Cardiol 1998, 82:254-255.
122. Celermajer D.S., Cullen S., Deanfield J.E. Impairment of endothelium-dependent pulmonary artery relaxation in children with congenital heart disease and abnormal pulmonary hemodynamics. Circulation 1993, 87:440-446.
123. Giaid A., Yanagisawa M., Langleben D., et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993, 328:1732-1739.
124. Dupuis J., Stewart D.J., Cernacek P., et al. Human pulmonary circulation is an important site for both clearance and production of endothelin-1. Circulation 1996, 94:1578-1584.
125. Costard-Jackle A., Fowler M.B. Influence of preoperative pulmonary artery pressure on mortality after heart transplantation: testing of potential reversibility of pulmonary hypertension with nitroprusside is useful in defining a high risk group. J Am Coll Cardiol 1992, 19:48-54.
126. Klotz S., Wenzelburger F., Stypmann J., et al. Reversible pulmonary hypertension in heart transplant candidates: to transplant or not to transplant. Ann Thorac Surg 2006, 82:1770-1773.
127. Drakos S.G., Kfoury A.G., Gilbert E.M., et al. Effect of reversible pulmonary hypertension on outcomes after heart transplantation. J Heart Lung Transplant 2007, 26:319-323.
128. Stevenson L.W., Tillisch J.H., Hamilton M., et al. Importance of hemodynamic response to therapy in predicting survival with ejection fraction less than or equal to 20% secondary to ischemic or nonischemic dilated cardiomyopathy. Am J Cardiol 1990, 66:1348-1354.
129. Stevenson W.G., Stevenson L.W., Middlekauff H.R., et al. Improving survival for patients with advanced heart failure: a study of 737 consecutive patients. J Am Coll Cardiol 1995, 26:1417-1423.
130. Meta-analysis Research Group in Echocardiography (MeRGE) Heart Failure Collaborators Independence of restrictive filling pattern and LV ejection fraction with mortality in heart failure: an individual patient meta-analysis. Eur J Heart Fail 2008, 10:786-792.
131. de Groote P., Millaire A., Foucher-Hossein C., et al. Right ventricular ejection fraction is an independent predictor of survival in patients with moderate heart failure. J Am Coll Cardiol 1998, 32:948-954.
132. Kjaergaard J., Akkan D., Iversen K.K., et al. Right ventricular dysfunction as an independent predictor of short- and long-term mortality in patients with heart failure. Eur J Heart Fail 2007, 9:610-616.
133. Damy T., Kallvikbacka-Bennett A., Goode K., et al. Prevalence of, associations with, and prognostic value of tricuspid annular plane systolic excursion (TAPSE) among out-patients referred for the evaluation of heart failure. J Card Fail 2012, 18:216-225.
134. Morrison D., Goldman S., Wright A.L., et al. The effect of pulmonary hypertension on systolic function of the right ventricle. Chest 1983, 84:250-257.
135. Gavazzi A., Ghio S., Scelsi L., et al. Response of the right ventricle to acute pulmonary vasodilation predicts the outcome in patients with advanced heart failure and pulmonary hypertension. Am Heart J 2003, 145:310-316.
136. Nagendran J, Gurtu V, Fu DZ, et al. A dynamic and chamber-specific mitochondrial remodeling in right ventricular hypertrophy can be therapeutically targeted. J Thorac Cardiovasc Surg 2008;136:168-78, 78 e1-3.
137. Mikus E., Stepanenko A., Krabatsch T., et al. Reversibility of fixed pulmonary hypertension in left ventricular assist device support recipients. Eur J Cardiothorac Surg 2011, 40:971-977.
138. Nkomo V.T., Gardin J.M., Skelton T.N., et al. Burden of valvular heart diseases: a population-based study. Lancet 2006, 368:1005-1011.
139. Braunwald E., Braunwald N.S., Ross J., et al. Effects of mitral-valve replacement on the pulmonary vascular dynamics of patients with pulmonary hypertension. N Engl J Med 1965, 273:509-514.
140. Camara M.L., Aris A., Padro J.M., et al. Long-term results of mitral valve surgery in patients with severe pulmonary hypertension. Ann Thorac Surg 1988, 45:133-136.
141. Chaffin J.S., Daggett W.M. Mitral valve replacement: a nine-year follow-up of risks and survivals. Ann Thorac Surg 1979, 27:312-319.
142. Kabbani S.S., Bashour T., Dunlap R., et al. Mitral stenosis with severe pulmonary hypertension. Tex Heart Inst J 1982, 9:307-310.
143. Vincens J.J., Temizer D., Post J.R., et al. Long-term outcome of cardiac surgery in patients with mitral stenosis and severe pulmonary hypertension. Circulation 1995, 92:II137-II142.
144. Mubeen M., Singh A.K., Agarwal S.K., et al. Mitral valve replacement in severe pulmonary arterial hypertension. Asian Cardiovasc Thorac Ann 2008, 16:37-42.
145. Fawzy M.E., Hassan W., Stefadouros M., et al. Prevalence and fate of severe pulmonary hypertension in 559 consecutive patients with severe rheumatic mitral stenosis undergoing mitral balloon valvotomy. J Heart Valve Dis 2004, 13:942-947. [discussion 7-8].
146. Gorlin R., Mc M.I., Medd W.E., et al. Dynamics of the circulation in aortic valvular disease. Am J Med 1955, 18:855-870.
147. Basu B., Cherian G., Krishnaswami S., et al. Severe pulmonary hypertension in advanced aortic valve disease. Br Heart J 1978, 40:1310-1313.
148. Malouf J.F., Enriquez-Sarano M., Pellikka P.A., et al. Severe pulmonary hypertension in patients with severe aortic valve stenosis: clinical profile and prognostic implications. J Am Coll Cardiol 2002, 40:789-795.
149. Johnson L.W., Hapanowicz M.B., Buonanno C., et al. Pulmonary hypertension in isolated aortic stenosis. Hemodynamic correlations and follow-up. J Thorac Cardiovasc Surg 1988, 95:603-607.
150. Tracy G.P., Proctor M.S., Hizny C.S. Reversibility of pulmonary artery hypertension in aortic stenosis after aortic valve replacement. Ann Thorac Surg 1990, 50:89-93.
151. Aragam J.R., Folland E.D., Lapsley D., et al. Cause and impact of pulmonary hypertension in isolated aortic stenosis on operative mortality for aortic valve replacement in men. Am J Cardiol 1992, 69:1365-1367.
152. Saraiva R.M., Matsumura Y., Yamano T., et al. Relation of left atrial dysfunction to pulmonary artery hypertension in patients with aortic stenosis and left ventricular systolic dysfunction. Am J Cardiol 2010, 106:409-416.
153. Ben-Dor I., Goldstein S.A., Pichard A.D., et al. Clinical profile, prognostic implication, and response to treatment of pulmonary hypertension in patients with severe aortic stenosis. Am J Cardiol 2011, 107:1046-1051.